Literature DB >> 32549948

Are Repeated Cycles of Intravenous Immunoglobulin Justified in Patients With Poorly Responsive Guillain-Barré Syndrome?

Hussein Algahtani1, Bader Shirah2, Khalid Alrefaei3, Mohammed Albassam3, Nawal Abdelghaffar4.   

Abstract

Guillain-Barré syndrome (GBS) is a life-threatening form of inflammatory polyneuropathy. Immunotherapy with intravenous immunoglobulin (IVIG) has been used successfully in the treatment of GBS. In this case report, we present a severe axonal form of GBS that showed improvement after 3 cycles of IVIG. Repeated cycles of IVIG may be an option for treating severe forms of GBS not responding to the first course of such treatment. The recent work suggests that patients who are severely affected and have severe gadolinium enhancement on the magnetic resonance imaging of the spine should be considered for retreatment with IVIG. Although the cost of management was high, the outcome was excellent, which is definitely considered a reasonable approach. This case report is an urgent call for performing large multicenter trials on the use of repeated cycles of IVIG in the management of severe cases of GBS.
© The Author(s) 2019.

Entities:  

Keywords:  Guillain-Barré syndrome; Saudi Arabia; intravenous immunoglobulin; poor response; repeated cycle

Year:  2019        PMID: 32549948      PMCID: PMC7271620          DOI: 10.1177/1941874419893570

Source DB:  PubMed          Journal:  Neurohospitalist        ISSN: 1941-8744


  29 in total

1.  Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome.

Authors:  Brigitte Buchwald; Raheleh Ahangari; Andreas Weishaupt; Klaus V Toyka
Journal:  Ann Neurol       Date:  2002-06       Impact factor: 10.422

Review 2.  Guillain-Barré syndrome.

Authors:  Nobuhiro Yuki; Hans-Peter Hartung
Journal:  N Engl J Med       Date:  2012-06-14       Impact factor: 91.245

3.  Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial.

Authors:  Christa Walgaard; Bart C Jacobs; Hester F Lingsma; Ewout W Steyerberg; David R Cornblath; Pieter A van Doorn
Journal:  J Peripher Nerv Syst       Date:  2018-09-24       Impact factor: 3.494

4.  Experience with Guillain-Barré syndrome in a neurological Intensive Care Unit.

Authors:  P González; X García; A Guerra; J C Arango; H Delgado; C S Uribe; J Sará; J C López de Mesa; O Hernández
Journal:  Neurologia       Date:  2014-12-23       Impact factor: 3.109

5.  Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial.

Authors:  R van Koningsveld; P I M Schmitz; F G Avander Meché; L H Visser; J Meulstee; P A van Doorn
Journal:  Lancet       Date:  2004-01-17       Impact factor: 79.321

6.  The Pathogenesis of the Demyelinating Form of Guillain-Barre Syndrome (GBS): Proteo-peptidomic and Immunological Profiling of Physiological Fluids.

Authors:  Rustam H Ziganshin; Olga M Ivanova; Yakov A Lomakin; Alexey A Belogurov; Sergey I Kovalchuk; Igor V Azarkin; Georgij P Arapidi; Nikolay A Anikanov; Victoria O Shender; Mikhail A Piradov; Natalia A Suponeva; Anna A Vorobyeva; Alexander G Gabibov; Vadim T Ivanov; Vadim M Govorun
Journal:  Mol Cell Proteomics       Date:  2016-05-03       Impact factor: 5.911

Review 7.  Guillain-Barré Syndrome.

Authors:  Peter D Donofrio
Journal:  Continuum (Minneap Minn)       Date:  2017-10

Review 8.  Axonal Guillain-Barré syndrome: concepts and controversies.

Authors:  Satoshi Kuwabara; Nobuhiro Yuki
Journal:  Lancet Neurol       Date:  2013-12       Impact factor: 44.182

9.  Treatment guidelines for Guillain-Barré Syndrome.

Authors:  A K Meena; S V Khadilkar; J M K Murthy
Journal:  Ann Indian Acad Neurol       Date:  2011-07       Impact factor: 1.383

Review 10.  An update in guillain-barré syndrome.

Authors:  J B Winer
Journal:  Autoimmune Dis       Date:  2014-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.